Instituto Médico Río Cuarto

Institución privada con internación

Hipólito Yrigoyen 1020, X5800 Río Cuarto, Córdoba, Argentina

Websitehttp://www.imrc.com.ar

Select an option

I am a doctor

I am a sponsor

Specializations

Onco-hematología

Insuficiencia cardiaca

Cardiovascular

Virus sincitial respiratorio

Infección del tracto respiratorio

Cáncer urotelial

Fibrosis pulmonar idiopática

Bronquiectasia por fibrosis no quística

Fibrosis pulmonar

Hipertensión arterial pulmonar

Covid-19

Our team

Medical staff

Alejo Lingua

Sebastián Etchevers

Osvaldo Federico Magri

Maria Estefania Orihuela

Clarisa Rins

Antonella Rodolfi

Rodrigo Carnero

Fernando Javier Bordese

Open studies

Cardiovascular disease

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more

Lung cancer

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more

Obesity

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more

Renal disease

Elevated Lipoprotein A

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more

Respiratory syncytial virus

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease - ShionogiSee more

Pulmonary fibrosis

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) - TETON-PPF - United TherapeuticsSee more